Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm using Venetoclax and SL-401

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the effectiveness of venetoclax, SL-401, and chemotherapy in treating patients with newly diagnosed blastic plasmacytoid dendritic cell neoplasm (BPDCN). Venetoclax works by inhibiting enzymes necessary for tumor cell growth, while SL-401 targets IL-3 receptors on tumor cells to deliver a toxic agent that kills them. The study aims to assess progression-free survival at 12 months, safety, and overall response rates among participants. Additionally, it explores the molecular characteristics of the disease and the potential for stem cell transplantation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Treatment naïve or relapsed refractory patients with histologically confirmed diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) per 2016 WHO criteria
2. Front line participants may have received emergent chemotherapy prior to study enrollment:

   1. One prior cycle of SL-401, or other BPDCN-directed therapy, will be allowed prior to entering the study.
   2. Prior or concomitant doses of ARA-C (cytarabine) or Hydroxyurea are allowed on before or during the study for proliferative disease due to BPDCN.
3. Relapsed/refractory participants may have received at least one prior cycle of therapy.
4. Age ≥ 18 years
5. ECOG performance status 0, 1, or 2 (see APPENDIX B)
6. Adequate organ function as defined by:

   * Albumin ≥ 3.2 g/dL (in the absence of receipt of intravenous albumin in the previous 72 hours)
   * Serum creatinine \< 1.5x ULN
   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5x ULN
   * Total bilirubin \< 1.5x ULN (if total bilirubin is \> 1.5x but \< 3x ULN, and thought to be elevated due to Gilbert's disease or the patient's BPDCN, the subject may be eligible but must discuss with the PI)
7. Ability to understand and the willingness to sign a written informed consent document.
8. Able to adhere to study visit schedule and other protocol requirements including follow-up for survival assessment
9. Women of child-bearing potential and men enrolled on this protocol must agree to use adequate contraception for the duration of study participation and for 2 months after completion VEN administration. Acceptable birth control methods allowed to be used while on study include:

   * Birth control pills or injections
   * Intrauterine devices (IUDs)
   * Double-barrier methods for example condom in combination with spermicide. Males should not donate sperm while on study and for at least 8 weeks after the last dose of SL-401.
10. Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment.

Exclusion Criteria:

1. Participants is pregnant or breastfeeding
2. Known active hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
3. Major surgery or radiation therapy within 14 days prior to the first study dose
4. Symptomatic or untreated leptomeningeal disease or spinal cord compression
5. Participants with active heart disease (New York Heart Association (NYHA) class 3-4 as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last 6 months)
6. Malabsorption syndrome or other conditions that preclude enteral route of administration
7. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the participants inappropriate for enrollment into this study

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Naveen Pemmaraju — M.D. Anderson Cancer Center
• Study coordinator: Naveen Pemmaraju
• Email: npemmaraju@mdanderson.org
• Phone: 713-792-4956

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• Combining SL-401 with Azacitidine or Venetoclax for treating blood cancers

  This study is testing if combining a new treatment called SL-401 with existing drugs azacitidine or venetoclax can help people with certain blood cancers feel better and improve their outcomes.

  Recruiting at 3 sites Phase 1 Dana-Farber Cancer Institute · Duarte, California and 2 other locations · NCT03113643

• Preventing heart problems in overweight/obese young sarcoma survivors with tirzepatide

  This feasibility study tests whether tirzepatide can be safely given to overweight or obese young adults (18–39) who have completed doxorubicin for soft tissue or bone sarcoma to see if it’s feasible to use in the first year after therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07874828

• Predicting lymphedema risk in inflammatory breast cancer patients using preoperative body impedance analysis

  This study tests whether a preoperative bioimpedance test can help identify IBC patients who are at risk for developing lymphedema.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07855627

• Precision genomic testing to guide first-line LBCL treatment readiness

  Doctors will see if a tumor genomic test can help tailor first-line treatment for adults with LBCL by the start of the second cycle of standard therapy.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07829445

• Using Apple Vision Pro in image-guided procedures

  This study tests whether the Apple Vision Pro can be used during CT-guided biopsy procedures to help with imaging and guidance.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07819513

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.